Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2748-2757

  Lemaire, Sandrine ^a   Van Bambeke, Françoise ^a   Mingeot Leclercq, Marie Paule ^a   Tulkens, Paul M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL TYPE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNODETECTION; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; DAPTOMYCIN; DOGS; HUMANS; KIDNEY; MACROPHAGES; P-GLYCOPROTEIN; PHAGOCYTOSIS; STAPHYLOCOCCUS AUREUS;

EID: 34547616150     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00090-07     Document Type: Article

References (70)

1. Acharya, P., T. T. Tran, J. W. Polli, A. Ayrton, H. Ellens, and J. Bentz. 2006. P-glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites. Biochemistry 45:15505-15519.
2. Andrew, J. H., M. C. Wale, L. J. Wale, and D. Greenwood. 1987. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J. Antimicrob. Chemother. 20:213-221.
3. Barcia-Macay, M., S. Lemaire, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:1177-1184.
4. Barcia-Macay, M., C. Seral, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851.
5. Beauchamp, D., P. Gourde, M. Simard, and M. G. Bergeron. 1994. Subcellular distribution of daptomycin given alone or with tobramycin in renal proximal tubular cells. Antimicrob. Agents Chemother. 38:189-194.
6. Beeler, T. J., I. Jona, and A. Martonosi. 1979. The effect of ionomycin on calcium fluxes in sarcoplasmic reticulum vesicles and liposomes. J. Biol. Chem. 254:6229-6231.
7. Brouillard, F., D. Tondelier, A. Edelman, and M. Baudouin-Legros. 2001. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res. 61:1693-1698.
8. Carlier, M. B., I. Garcia-Luque, J. P. Montenez, P. M. Tulkens, and J. Piret. 1994. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int. J. Tissue React. 16:211-220.
9. Clark, R., I. D. Kerr, and R. Callaghan. 2006. Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br. I. Pharmacol. 149:506-515.
10. Ehlert, F., and H. C. Neu. 1987. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur. J. Clin. Microbiol. 6:84-90.
11. Eliopoulos, G. M., S. Willey, E. Reiszner, P. G. Spitzer, G. Caputo, and R. C. Moellering, Jr. 1986. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.
12. Evers, R., M. Kool, A. J. Smith, L. van Deemter, M. de Haas, and P. Borst. 2000. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br. J. Cancer 83:366-374.
13. Foster, T. J. 2005. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3:948-958.
14. French, G. L. 2006. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J. Antimicrob. Chemother. 58:1107-1117.
15. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38:51-58.
16. Hyafil, F., C. Vergely, V. P. Du, and T. Grand-Perret. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602.
17. Ichibangase, Y., M. Yamamoto, M. Yasuda, N. Houki, and M. Nobunaga. 1998. Induction of drug resistance to gold sodium thiomalate in a monocyte cell line, THP-1. Clin. Rheumatol. 17:214-218.
18. Juliano, R. L., and V. Ling. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-162.
19. Kao, J. P., A. T. Harootunian, and R. Y. Tsien. 1989. Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J. Biol. Cham. 264:8179-8184.
20. Katragadda, S., B. Budda, B. S. Anand, and A. K. Mitra. 2005. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin. Drug Deliv. 2:683-705.
21. Keller, R. P., H. J. Altermatt, P. Donatsch, H. Zihlmann, J. A. Laissue, and P. C. Hiestand. 1992. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer 51:433-438.
22. Lawen, A., R. Traber, and D. Geyl. 1991. In vitro biosynthesis of [Thr2, Leu5, D-Hiv8, Leu10]cyclosporin, a cyclosporin-related immunosuppressive peptolide. Biomed. Biochim. Acta 50:S260-S263.
23. Lee, S. Y., H. W. Fan, J. L. Kuti, and D. P. Nicolau. 2006. Update on daptomycin: the first approved lipopeptide antibiotic. Expert. Opin. Pharmacother. 7:1381-1397.
24. Leith, C. P., I. M. Chen, K. J. Kopecky, F. R. Appelbaum, D. R. Head, J. E. Godwin, J. K. Weick, and C. L. Willman. 1995. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 86:2329-2342.
25. Lemaire, S., T. Bogdanovitch, S. Chavez-Bueno, P. D. Savage, F. Van Bambeke, P. Appelbaum, and P. M. Tulkens. 2006. Bactericidal activity of ceragenin CSA-13 against intracellular MSSA, hospital-acquired (HA) and community-acquired (CA) MRSA, and VISA in THP-1 macrophages: relation to cellular toxicity?, abstr. A-0633. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 27 to 30 September 2006.
26. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Activity of three β-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904.
27. Leslie, E. M., R. G. Deeley, and S. P. Cole. 2005. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204:216-237.
28. Liu, X., M. Tu, R. S. Kelly, C. Chen, and B. J. Smith. 2004. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos. 32:132-139.
29. Louvard, D. 1980. Apical membrane aminopeptidase appears at site of cell-cell contact in cultured kidney epithelial cells. Proc. Natl. Acad. Sci. USA 77:4132-4136.
30. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
31. Lowy, F. D. 2000. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol. 8:341-343.
32. Melkonyan, H., C. Sorg, and M. Klempt. 1996. Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO). Nucleic Acids Res. 24:4356-4357.
33. Michot, J. M., M. F. Heremans, N. E. Caceres, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. Antimicrob. Agents Chemother. 50:1689-1695.
34. Michot, J. M., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob. Agents Chemother. 48:2673-2682.
35. Minderman, H., U. Vanhoefer, K. Toth, M. B. Yin, M. D. Minderman, C. Wrzosek, M. L. Slovak, and Y. M. Rustum. 1996. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 25:14-20.
36. Minta, A., J. P. Kao, and R. Y. Tsien. 1989. Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. J. Biol. Chem. 264:8171-8178.
37. Oleson, F. B., Jr., C. L. Berman, J. B. Kirkpatrick, K. S. Regan, J. J. Lai, and F. P. Tally. 2000. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother. 44:2948-2953.
38. Papadopoulos, S., A. M. Ball, S. E. Liewer, C. A. Martin, P. S. Winstead, and B. S. Murphy. 2006. Rhabdomyolysis during therapy with daptomycin. Clin. Infect. Dis. 42:e108-e110.
39. Ramagli, L. S. 1999. Quantifying protein in 2-D PAGE solubilization buffers. Methods Mol. Biol. 112:99-103.
40. Raub, T. J. 2006. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3:3-25.
41. Robertson, D., H. F. Paterson, P. Adamson, A. Hall, and P. Monaghan. 1995. Ultrastructural localization of ras-related proteins using epitope-tagged plasmids. J. Histochem. Cytochem. 43:471-480.
42. Safa, A. R. 1988. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. Natl. Acad. Sci. USA 85:7187-7191.
43. Saleh, M., J. C. Mathison, M. K. Wolinski, S. J. Bensinger, P. Fitzgerald, N. Droin, R. J. Ulevitch, D. R. Green, and D. W. Nicholson. 2006. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 440:1064-1068.
44. Sandig, M., E. Negrou, and K. A. Rogers. 1997. Changes in the distribution of LFA-1, catenins, and F-actin during transendothelial migration of monocytes in culture. J. Cell Sci. 110:2807-2818.
45. Serai, C., M. Barcia-Macay, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2005. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J. Antimicrob. Chemother. 55:511-517.
46. Serai, C., S. Carryn, P. M. Tulkens, and F. Van Bambeke. 2003. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J. Antimicrob. Chemother. 51:1167-1173.
47. Seral, C., J. M. Michot, H. Chanteux, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2003. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob. Agents Chemother. 47:1047-1051.
48. Serai, C., F. Van Bambeke, and P. M. Tulkens. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283-2292.
49. Shitara, Y., T. Horie, and Y. Sugiyama. 2006. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27:425-446.
50. Sikri, V., D. Pal, R. Jain, D. Kalyani, and A. K. Mitra. 2004. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. Am. J. Ther. 11:433-442.
51. Silverman, J. A., L. I. Mortin, A. D. Vanpraagh, T. Li, and J. Alder. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191:2149-2152.
52. Smith, A. J., J. L. Timmermans-Hereijgers, B. Roelofsen, K. W. Wirtz, W. J. van Blitterswijk, J. J. Smit, A. H. Schinkel, and P. Borst. 1994. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett. 354:263-266.
53. Straus, S. K., and R. E. Hancock. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223.
54. Takara, K., M. Tsujimoto, M. Kokufu, N. Ohnishi, and T. Yokoyama. 2003. Up-regulation of MDR1 function and expression by cisplatin in LLC-PK1 cells. Biol. Pharm. Bull. 26:205-209.
55. Tarasova, N. I., R. Seth, S. G. Tarasov, T. Kosakowska-Cholody, C. A. Hrycyna, M. M. Gottesman, and C. J. Michejda. 2005. Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J. Med. Chem. 48:3768-3775.
56. Tran, T. T., A. Mittal, T. Aldinger, J. W. Polli, A. Ayrton, H. Ellens, and J. Bentz. 2005. The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys. J. 88:715-738.
57. Tsuchiya, S., M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26:171-176.
58. Tyteca, D., S. P. Van Der, M. Mettlen, F. Van Bambeke, P. M. Tulkens, M. P. Mingeot-Leclercq, and P. J. Courtoy. 2002. Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. Exp. Cell Res. 281:86-100.
59. Van Bambeke, F., E. Balzi, and P. M. Tulkens. 2000. Antibiotic efflux pumps. Biochem. Pharmacol. 60:457-470.
60. Van Bambeke, F., M. Barcia-Macay, S. Lemaire, and P. M. Tulkens. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Dev. 9:218-230.
61. Van Bambeke, F., J. M. Michot, and P. M. Tulkens. 2003. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J. Antimicrob. Chemother. 51:1067-1077.
62. Vance-Bryan, K., T. A. Larson, J. C. Rotschafer, and J. P. Toscano. 1992. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 36:2334-2337.
63. Van der Auwera, P., G. Petrikkos, T. Matsumoto, and M. Husson. 1988. Influence of LY146032 on human polymorphonuclear leucocytes in vitro. J. Antimicrob. Chemother. 21:57-63.
64. van der Heijden, J., M. C. de Jong, B. A. Dijkmans, W. F. Lems, R. Oerlemans, I. Kathmann, C. G. Schalkwijk, G. L. Schefler, R. J. Scheper, and G. Jansen. 2004. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann. Rheum. Dis. 63:138-143.
65. Vandevuer, S., F. Van Bambeke, P. M. Tulkens, and M. Prevost. 2006. Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying Crosslin king data: insight into the mechanism of ligand migration and binding sites. Proteins 63:466-478.
66. Varma, M. V., O. P. Perumal, and R. Panchagnula. 2006. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr. Opin. Chem. Biol. 10:367-373.
67. Wise, R., T. Gee, J. M. Andrews, B. Dvorchik, and G. Marshall. 2002. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. 46:31-33.
68. Woehlck, H. J., and F. V. McCann. 1986. Action potentials in human macrophages are calcium spikes. Cell Biol. Int. Rep. 10:517-525.
69. Yu, E. W., J. R. Aires, and H. Nikaido. 2003. AcrB multidrug efflux pump of Escherichia coli: composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. J. Bacteriol. 185:5657-5664.
70. Zhou, Y., M. M. Gottesman, and I. Pastan. 1999. Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippase. Mol. Cell. Biol. 19:1450-1459.